<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112983</url>
  </required_header>
  <id_info>
    <org_study_id>ALEXION-C04-001</org_study_id>
    <secondary_id>UCLA-0406101-01</secondary_id>
    <secondary_id>CDR0000409569</secondary_id>
    <nct_id>NCT00112983</nct_id>
  </id_info>
  <brief_title>Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <official_title>TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. The use of eculizumab may prevent leukemia and stop the destruction of red&#xD;
      blood cells in patients with paroxysmal nocturnal hemoglobinuria.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well eculizumab works in treating&#xD;
      patients with paroxysmal nocturnal hemoglobinuria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of eculizumab in patients with transfusion-dependent hemolytic&#xD;
           paroxysmal nocturnal hemoglobinuria.&#xD;
&#xD;
        -  Determine the efficacy of this drug, in terms of hemoglobin stabilization and the number&#xD;
           of packed red blood cell units transfused during the 26-week treatment period, in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the occurrence of transfusion avoidance, hemolysis (measured by lactate&#xD;
           dehydrogenase [LDH] area under the curve), and the changes in fatigue during the 26-week&#xD;
           treatment period in patients treated with this drug vs placebo.&#xD;
&#xD;
        -  Compare LDH changes, quality of life changes, thrombosis, platelet activity, nitric&#xD;
           oxide, and free hemoglobin measures during the 26-week treatment period in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to the number of packed red blood cell (PRBC) units transfused 1&#xD;
      year prior to screening (&lt; 15 units vs 15-25 units vs &gt; 25 units). Patients are randomized to&#xD;
      1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Within 10 days after PRBC transfusion (administered during the study observation&#xD;
           period), patients receive placebo IV over 30 minutes once a week for 5 weeks and then&#xD;
           once every 2 weeks for 21 weeks.&#xD;
&#xD;
        -  Arm II: Within 10 days after PRBC transfusion (administered during the study observation&#xD;
           period), patients receive eculizumab IV over 30 minutes once a week for 5 weeks and then&#xD;
           once every 2 weeks for 21 weeks.&#xD;
&#xD;
      Quality of life is assessed at baseline; at weeks 0-4, 12, 20, and 26 during study treatment;&#xD;
      then at weeks 1, 2, 4, and 8 after completion of study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed at weeks 1, 2, 4, and 8.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 75 patients (37 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>eculizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
          -  Must have required ≥ 4 episodes of transfusions for anemia or anemia-related symptoms&#xD;
             within the past year&#xD;
&#xD;
               -  Mean pre-transfusion hemoglobin ≤ 10. 5 g/dL over the past year&#xD;
&#xD;
          -  Glycosylphosphatidylinositol (GPI)-deficient red blood cell clone (type III cells) of&#xD;
             ≥ 10% by flow cytometry&#xD;
&#xD;
          -  Must have received 1 packed red blood cell transfusion during the study observation&#xD;
             period (within 48 hours of the hemoglobin level that precipitated the transfusion) and&#xD;
             within 1.5 g/dL of the mean pre-transfusion hemoglobin level over the past year&#xD;
&#xD;
               -  Pre-transfusion hemoglobin ≤ 9 g/dL with symptoms&#xD;
&#xD;
               -  Pre-transfusion hemoglobin ≤ 7 g/dL without symptoms&#xD;
&#xD;
          -  Received Neisseria meningitidis vaccination at least 2 weeks before initiation of&#xD;
             study therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Lactate dehydrogenase ≥ 1.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No known or suspected active bacterial infection&#xD;
&#xD;
          -  No recurrent bacterial infections&#xD;
&#xD;
          -  No history of meningococcal disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No known or suspected hereditary complement deficiency&#xD;
&#xD;
          -  No other condition that would increase the patient's risk or confound the outcome of&#xD;
             the study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bone marrow transplantation&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed*&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed**&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior participation in another investigational drug trial&#xD;
&#xD;
          -  More than 30 days since prior investigational agents, devices, or procedures&#xD;
&#xD;
          -  Concurrent immunosuppressants allowed*&#xD;
&#xD;
          -  Concurrent warfarin allowed provided INR level is stable for the past 4 weeks and&#xD;
             expected to remain stable during observation and study treatment&#xD;
&#xD;
          -  Concurrent iron supplements or folic acid allowed**&#xD;
&#xD;
          -  Concurrent low-molecular weight heparin allowed** NOTE: *Provided dose is stable for&#xD;
             the past 26 weeks and during study observation and treatment&#xD;
&#xD;
        NOTE: **Provided dose is stable for the past 4 weeks and expected to remain stable (or&#xD;
        decrease for corticosteroids) during study observation and treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Paquette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

